BRPI0615163A2 - composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5 - Google Patents
composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5Info
- Publication number
- BRPI0615163A2 BRPI0615163A2 BRPI0615163A BRPI0615163A BRPI0615163A2 BR PI0615163 A2 BRPI0615163 A2 BR PI0615163A2 BR PI0615163 A BRPI0615163 A BR PI0615163A BR PI0615163 A BRPI0615163 A BR PI0615163A BR PI0615163 A2 BRPI0615163 A2 BR PI0615163A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- mglur5
- methods
- pharmaceutical composition
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 230000004913 activation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70794605P | 2005-08-15 | 2005-08-15 | |
| PCT/US2006/030392 WO2007021573A1 (en) | 2005-08-15 | 2006-08-04 | Substituted piperazines as metabotropic glutamate receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0615163A2 true BRPI0615163A2 (pt) | 2016-09-13 |
Family
ID=37451198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0615163A BRPI0615163A2 (pt) | 2005-08-15 | 2006-08-04 | composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20070037820A1 (zh) |
| EP (1) | EP1919901A1 (zh) |
| JP (1) | JP2009504734A (zh) |
| KR (1) | KR20080057224A (zh) |
| CN (1) | CN101287722A (zh) |
| AR (1) | AR057728A1 (zh) |
| AU (1) | AU2006280231A1 (zh) |
| BR (1) | BRPI0615163A2 (zh) |
| CA (1) | CA2616307A1 (zh) |
| IL (1) | IL188806A0 (zh) |
| MX (1) | MX2008001606A (zh) |
| NO (1) | NO20080670L (zh) |
| TW (1) | TW200800946A (zh) |
| UY (1) | UY29735A1 (zh) |
| WO (1) | WO2007021573A1 (zh) |
| ZA (1) | ZA200801035B (zh) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0711521D0 (en) * | 2007-06-14 | 2007-07-25 | Glaxo Group Ltd | Novel compounds |
| EP2252599A1 (en) * | 2008-03-18 | 2010-11-24 | Glaxo Group Limited | Triazole amide derivatives for use in therapy |
| ES2526966T3 (es) | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
| US8658635B2 (en) * | 2008-06-05 | 2014-02-25 | Glaxosmithkline Intellectual Property Development Limited | Benzpyrazol derivatives as inhibitors of PI3 kinases |
| US8765743B2 (en) * | 2008-06-05 | 2014-07-01 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| KR101771193B1 (ko) | 2009-04-30 | 2017-09-05 | 글락소 그룹 리미티드 | Ｐｉ3키나아제 억제제로서 옥사졸 치환된 인다졸 |
| WO2012031383A1 (zh) * | 2010-09-06 | 2012-03-15 | 中国科学院广州生物医药与健康研究院 | 酰胺类化合物 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
| US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
| US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
| US8796467B2 (en) * | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
| US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
| US8716277B2 (en) * | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
| US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
| US8937176B2 (en) * | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
| US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
| CN113087669B (zh) * | 2019-12-23 | 2023-11-17 | 南京药石科技股份有限公司 | 一种4-氰基-5-溴嘧啶的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ219380A (en) * | 1986-02-27 | 1990-06-26 | Duphar Int Res | (n-piperidinyl)- and (n-piperazinyl)-methylazole derivatives and pharmaceutical compositions |
| US5681956A (en) * | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| US6313127B1 (en) * | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| WO2003093236A1 (en) * | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
| JP2006506340A (ja) * | 2002-08-09 | 2006-02-23 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール |
| JP2006516656A (ja) * | 2003-01-28 | 2006-07-06 | アヴェンティス ファーマ エス．エー． | Ｎ−アリールヘテロ芳香族物質、それを含む組成物およびその用途 |
| AR044586A1 (es) * | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| WO2005077373A2 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
-
2006
- 2006-08-03 TW TW095128483A patent/TW200800946A/zh unknown
- 2006-08-04 US US11/498,835 patent/US20070037820A1/en not_active Abandoned
- 2006-08-04 US US11/997,444 patent/US20080312246A1/en not_active Abandoned
- 2006-08-04 EP EP06789371A patent/EP1919901A1/en not_active Withdrawn
- 2006-08-04 JP JP2008526973A patent/JP2009504734A/ja active Pending
- 2006-08-04 AU AU2006280231A patent/AU2006280231A1/en not_active Abandoned
- 2006-08-04 BR BRPI0615163A patent/BRPI0615163A2/pt not_active IP Right Cessation
- 2006-08-04 MX MX2008001606A patent/MX2008001606A/es not_active Application Discontinuation
- 2006-08-04 CN CNA2006800289759A patent/CN101287722A/zh active Pending
- 2006-08-04 KR KR1020087003230A patent/KR20080057224A/ko not_active Application Discontinuation
- 2006-08-04 CA CA002616307A patent/CA2616307A1/en not_active Abandoned
- 2006-08-04 WO PCT/US2006/030392 patent/WO2007021573A1/en active Application Filing
- 2006-08-08 UY UY29735A patent/UY29735A1/es not_active Application Discontinuation
- 2006-08-08 AR ARP060103442A patent/AR057728A1/es unknown
-
2008
- 2008-01-16 IL IL188806A patent/IL188806A0/en unknown
- 2008-01-31 ZA ZA200801035A patent/ZA200801035B/xx unknown
- 2008-02-05 NO NO20080670A patent/NO20080670L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1919901A1 (en) | 2008-05-14 |
| MX2008001606A (es) | 2008-04-14 |
| AR057728A1 (es) | 2007-12-12 |
| IL188806A0 (en) | 2008-08-07 |
| KR20080057224A (ko) | 2008-06-24 |
| AU2006280231A1 (en) | 2007-02-22 |
| JP2009504734A (ja) | 2009-02-05 |
| WO2007021573A1 (en) | 2007-02-22 |
| UY29735A1 (es) | 2007-02-28 |
| US20070037820A1 (en) | 2007-02-15 |
| CN101287722A (zh) | 2008-10-15 |
| NO20080670L (no) | 2008-04-01 |
| ZA200801035B (en) | 2008-12-31 |
| US20080312246A1 (en) | 2008-12-18 |
| TW200800946A (en) | 2008-01-01 |
| CA2616307A1 (en) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0615163A2 (pt) | composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5 | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2007002974A1 (es) | Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1. | |
| CL2007002578A1 (es) | Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer. | |
| BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
| BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
| CL2007003049A1 (es) | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. | |
| CL2007003495A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer. | |
| CL2007001882A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| BRPI0820665A2 (pt) | compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos | |
| BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| CL2007003202A1 (es) | Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular. | |
| BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
| CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
| CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
| CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
| BRPI0913585A2 (pt) | composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios | |
| CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
| BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| BRPI0818804A2 (pt) | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. | |
| BRPI0716844A2 (pt) | Inidores de quinase úteis para o tratamento de doenças proliferativas | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2007003756A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 20080015962/RJ DE 31/01/2008. |
|
| B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 - AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 - AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |